HSE defends Ireland's track record of providing access to new drugs

The HSE has defended Ireland's track record of providing access to new drugs when it responded to a claim by a pharmaceutical industry group that patients waited around a year and a half longer than their European counterparts to get the same medicines.

The Irish Pharmaceutical Healthcare Association (IPHA) based their claim on an analysis of 15 medicines which have completed their pharmacoeconomic assessment in Ireland but have yet to be reimbursed by the HSE.